Phase 1 study

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Merck Sharp & Dohme LLC
Registry number NCT07363590
Started 19 February 2026 Today 16 October 2026 Estimated completion 16 July 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Gold Coast University Hospital ( Site 1601) Southport QLD Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 21

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Has a body mass index between 18 and 32 kg/m\^2, inclusive

* Systemic lupus erythematosus (SLE): Has a diagnosis of SLE for at least 6 months and met the European Alliance of Associations for Rheumatology (EULAR)/ American College of Rheumatology (ACR) 2019 classification criteria

* SLE: Is taking at least one background therapy for SLE

* RA: Has a diagnosis of RA for at least 6 months and meets the 2010 ACR-EULAR classification criteria for RA

Exclusion Criteria:

* Has a known active infection (excluding fungal infection of nail beds), or any major episode of infection requiring hospitalization or treatment with anti-infectives within 8 weeks prior to the Day 1 dosing

* History of serious recurrent or chronic infection

* Is known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus

* Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB

* Has a significant or uncontrolled medical disease in any organ system not related to RA or SLE

* For RA participants, has a history of any arthritis with onset before age 17 years

* Has a current inflammatory condition other than SLE or RA that could interfere with disease activity assessments

* History of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before Day 1 dosing

* Has had a major surgery within 3 months prior to Screening or has a major surgery planned during the study.

* Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening

* Has a severe chronic pulmonary disease requiring oxygen therapy

* Has current active lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease

Dates on the record

Started 19 February 2026
Estimated completion 16 July 2029
Registry last updated 14 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 14 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.